Histone Modifications in Drug-resistant Cancers: From a Cancer Stem Cell and Immune Evasion Perspective

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2023 Jul 2

PMID 37394580

Authors

Ming Li Jin

Kwang Won Jeong

Affiliations

Soon will be listed here.

Abstract

The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of currently available anticancer therapies. Recent studies have shown that epigenetic reprogramming regulates the expression of characteristic marker proteins and tumor plasticity associated with cancer cell survival and metastasis in CSCs. CSCs also possess unique mechanisms to evade external attacks by immune cells. Hence, the development of new strategies to restore dysregulated histone modifications to overcome cancer resistance to chemotherapy and immunotherapy has recently attracted attention. Restoring abnormal histone modifications can be an effective anticancer strategy to increase the therapeutic effect of conventional chemotherapeutic and immunotherapeutic drugs by weakening CSCs or by rendering them in a naïve state with increased sensitivity to immune responses. In this review, we summarize recent findings regarding the role of histone modifiers in the development of drug-resistant cancer cells from the perspectives of CSCs and immune evasion. In addition, we discuss attempts to combine currently available histone modification inhibitors with conventional chemotherapy or immunotherapy.

Citing Articles

Melatonin Modulates ZAP70 and CD40 Transcripts via Histone Modifications in Canine Ileum Epithelial Cells.

Hong J, Adam S, Wang S, Huang H, Kim I, Ahmed A Vet Sci. 2025; 12(2).

PMID: 40005847 PMC: 11860356. DOI: 10.3390/vetsci12020087.

Advancing Pain Understanding and Drug Discovery: Insights from Preclinical Models and Recent Research Findings.

Asiri Y, Moni S, Ramar M, Chidambaram K Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598351 PMC: 11597627. DOI: 10.3390/ph17111439.

CCDC34 maintains stemness phenotype through β-catenin-mediated autophagy and promotes EGFR-TKI resistance in lung adenocarcinoma.

Yue P, He Y, Zuo R, Gong W, Wang Y, Chen L Cancer Gene Ther. 2024; 32(1):104-121.

PMID: 39587349 DOI: 10.1038/s41417-024-00843-y.

Editorial: Revisiting the challenges and opportunities in cancer drug resistance.

Dakal T, Sharma N, Sharma A Front Mol Biosci. 2024; 11:1497754.

PMID: 39403186 PMC: 11471640. DOI: 10.3389/fmolb.2024.1497754.

CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation-Mediated c-Myc Deubiquitylation to Facilitate Mutant TP53 Transcription.

Wang Z, Li Y, Yang J, Sun Y, He Y, Wang Y Adv Sci (Weinh). 2024; 11(34):e2404628.

PMID: 38981022 PMC: 11425638. DOI: 10.1002/advs.202404628.

References

Vasan N, Baselga J, Hyman D . A view on drug resistance in cancer. Nature. 2019; 575(7782):299-309. PMC: 8008476. DOI: 10.1038/s41586-019-1730-1. View

Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

Kreso A, Dick J . Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14(3):275-91. DOI: 10.1016/j.stem.2014.02.006. View

Saleh R, Elkord E . Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Semin Cancer Biol. 2019; 65:13-27. DOI: 10.1016/j.semcancer.2019.07.017. View

DOto A, Tian Q, Davidoff A, Yang J . Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther. 2017; 1(2):34-40. PMC: 5279889. View

Bayik D, Lathia J . Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021; 21(8):526-536. PMC: 8740903. DOI: 10.1038/s41568-021-00366-w. View

Yang Y, Wang Y . Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment. Front Immunol. 2021; 12:640369. PMC: 8051582. DOI: 10.3389/fimmu.2021.640369. View

Valkenburg K, Graveel C, Zylstra-Diegel C, Zhong Z, Williams B . Wnt/β-catenin Signaling in Normal and Cancer Stem Cells. Cancers (Basel). 2013; 3(2):2050-79. PMC: 3757404. DOI: 10.3390/cancers3022050. View

10.

Rheinbay E, Suva M, Gillespie S, Wakimoto H, Patel A, Shahid M . An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013; 3(5):1567-79. PMC: 3774301. DOI: 10.1016/j.celrep.2013.04.021. View

11.

Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle S, Ivanova E . PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010; 17(5):497-509. PMC: 2900858. DOI: 10.1016/j.ccr.2010.03.020. View

12.

Cho S, Lu M, He X, Ee P, Bhat U, Schneider E . Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A. 2011; 108(51):20778-83. PMC: 3251103. DOI: 10.1073/pnas.1019452108. View

13.

Wang Z, Da Silva T, Jin K, Han X, Ranganathan P, Zhu X . Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 2014; 74(21):6364-74. PMC: 4527315. DOI: 10.1158/0008-5472.CAN-14-2051. View

14.

Jin L, Vu T, Yuan G, Datta P . STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway. Cancer Res. 2017; 77(20):5464-5478. PMC: 5645244. DOI: 10.1158/0008-5472.CAN-17-0286. View

15.

Ghoshal P, Nganga A, Moran-Giuati J, Szafranek A, Johnson T, Bigelow A . Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res. 2009; 69(10):4380-7. DOI: 10.1158/0008-5472.CAN-08-3467. View

16.

Cochrane C, Szczepny A, Watkins D, Cain J . Hedgehog Signaling in the Maintenance of Cancer Stem Cells. Cancers (Basel). 2015; 7(3):1554-85. PMC: 4586784. DOI: 10.3390/cancers7030851. View

17.

Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P . Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010; 12(2):132-42. DOI: 10.1038/ncb2013. View

18.

To K, Polgar O, Huff L, Morisaki K, Bates S . Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res. 2008; 6(1):151-64. PMC: 3306834. DOI: 10.1158/1541-7786.MCR-07-0175. View

19.

Jin W . Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition. Cells. 2020; 9(1). PMC: 7017057. DOI: 10.3390/cells9010217. View

20.

Yuan Z, Guan Y, Chatterjee D, Chin Y . Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005; 307(5707):269-73. DOI: 10.1126/science.1105166. View